Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedMay 03, 2026
DataAggregated Company Financials
Companies1401
  • 7D0.4%
  • 3M-5.7%
  • 1Y8.2%
  • YTD-5.5%

Last week, the Healthcare industry hasn't moved much but Eli Lilly is up 9.0% in that time. As for the the longer term, the industry is up 8.2% over the past 12 months. As for the next few years, earnings are expected to grow by 17% per annum.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 03 May 2026US$6.2tUS$3.3tUS$118.0b23.6x52.4x1.9x
Tue, 31 Mar 2026US$6.0tUS$3.3tUS$126.5b21.9x47.3x1.8x
Thu, 26 Feb 2026US$6.6tUS$3.3tUS$126.3b26.2x52.2x2x
Sat, 24 Jan 2026US$6.7tUS$3.2tUS$130.6b28.5x51.1x2.1x
Mon, 22 Dec 2025US$6.5tUS$3.2tUS$135.2b26.2x48x2x
Wed, 19 Nov 2025US$6.2tUS$3.2tUS$133.4b25.1x46.8x2x
Fri, 17 Oct 2025US$6.0tUS$3.1tUS$140.4b25.4x42.5x1.9x
Sun, 14 Sep 2025US$5.7tUS$3.1tUS$137.6b22.7x41.6x1.9x
Tue, 12 Aug 2025US$5.4tUS$3.1tUS$139.8b23.4x38.5x1.7x
Thu, 10 Jul 2025US$5.5tUS$3.0tUS$127.9b24.2x43.2x1.8x
Sat, 07 Jun 2025US$5.4tUS$3.0tUS$127.2b24x42.7x1.8x
Mon, 05 May 2025US$5.6tUS$2.7tUS$126.2b24.8x44.1x2x
Wed, 02 Apr 2025US$5.7tUS$2.6tUS$81.6b26.3x69.4x2.1x
Fri, 28 Feb 2025US$5.8tUS$2.6tUS$79.7b26.1x73.3x2.2x
Sun, 26 Jan 2025US$6.0tUS$2.9tUS$85.5b27.9x70.7x2.1x
Tue, 24 Dec 2024US$5.8tUS$2.9tUS$78.3b27.1x73.5x2x
Thu, 21 Nov 2024US$5.9tUS$2.9tUS$77.0b27.4x76.7x2x
Sat, 19 Oct 2024US$6.2tUS$2.8tUS$58.7b32.2x105.7x2.2x
Mon, 16 Sep 2024US$6.3tUS$2.8tUS$60.0b30.6x105.4x2.2x
Wed, 14 Aug 2024US$6.0tUS$2.8tUS$55.4b31.1x108.3x2.1x
Fri, 12 Jul 2024US$6.2tUS$2.8tUS$62.2b30.7x100x2.2x
Sun, 09 Jun 2024US$6.2tUS$2.8tUS$63.6b30x97.5x2.2x
Tue, 07 May 2024US$6.1tUS$2.8tUS$64.3b31.1x94.4x2.1x
Thu, 04 Apr 2024US$6.2tUS$2.8tUS$84.0b32.4x73.6x2.2x
Sat, 02 Mar 2024US$6.2tUS$2.8tUS$85.1b31.9x73.3x2.2x
Mon, 29 Jan 2024US$6.3tUS$2.8tUS$90.7b32x69.7x2.2x
Wed, 27 Dec 2023US$6.2tUS$2.8tUS$91.5b33x67.4x2.2x
Fri, 24 Nov 2023US$5.8tUS$2.8tUS$91.2b28.2x63.8x2.1x
Sun, 22 Oct 2023US$5.7tUS$2.8tUS$99.6b25.6x57.7x2.1x
Tue, 19 Sep 2023US$6.0tUS$2.8tUS$98.6b29.1x60.8x2.2x
Thu, 17 Aug 2023US$6.1tUS$2.8tUS$99.2b28.7x61.9x2.2x
Sat, 15 Jul 2023US$6.0tUS$2.7tUS$110.9b26.3x53.9x2.2x
Mon, 12 Jun 2023US$6.0tUS$2.7tUS$110.4b25.2x53.9x2.2x
Wed, 10 May 2023US$6.0tUS$2.7tUS$111.9b24.4x53.8x2.2x
Price to Earnings Ratio

53.8x


Total Market Cap: US$6.0tTotal Earnings: US$111.9bTotal Revenue: US$2.7tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 52.4x which is lower than its 3-year average PE of 65.5x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have grown 6.5% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market0.85%
Healthcare0.40%
Healthcare Services3.48%
Pharma3.36%
Healthtech3.02%
Life Sciences-0.25%
Biotech-2.36%
Medical Equipment-4.20%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 55.2x.
    • Analysts are expecting annual earnings growth of 16.0%, which is higher than its past year's earnings growth of 13.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 23% over the next 5 years.
  • However this is lower than its past earnings growth rate of 40% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 14% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$963.339.0%
+US$71.0b		17.0%PE34.1x
ABBV AbbVieUS$206.604.0%
+US$14.0b		4.1%PE101.6x
UNH UnitedHealth GroupUS$368.783.9%
+US$12.6b		-7.8%PE27.8x
ELV Elevance HealthUS$372.688.1%
+US$6.1b		-9.1%PE15.4x
CNC CenteneUS$53.3427.5%
+US$5.8b		-11.3%PS0.1x

Latest News

LLY
US$963.33
Eli Lilly
7D
9.0%
1Y
17.0%
TEVA
US$34.95
Teva Pharmaceutical Industries
7D
14.1%
1Y
115.9%
AMGN
US$329.82
Amgen
7D
-4.3%
1Y
17.3%
REGN
US$701.42
Regeneron Pharmaceuticals
7D
-6.7%
1Y
15.8%
SYK
US$294.73
Stryker
7D
-10.0%
1Y
-22.1%
PFE
US$26.33
Pfizer
7D
-2.5%
1Y
8.8%

Pfizer: Why You Should Double Down Into Q1

May 01
HUM
US$233.63
Humana
7D
8.5%
1Y
-9.6%
ABBV
US$206.60
AbbVie
7D
4.0%
1Y
4.1%
UNH
US$368.78
UnitedHealth Group
7D
3.9%
1Y
-7.8%
ELV
US$372.68
Elevance Health
7D
8.1%
1Y
-9.1%

ELV: Regulatory And Margin Risks Will Pressure 2026 Earnings Visibility

The updated analyst price target for Elevance Health edges to $331 from $332, as analysts factor in slightly stronger revenue growth and profit margin assumptions, along with a modestly lower future P/E multiple, following a mix of recent upgrades, raised targets, and a few cautious revisions across the Street. Analyst Commentary Street research on Elevance Health has been mixed, with several firms lifting price targets while others trim expectations or shift to a more cautious stance.
BSX
US$56.50
Boston Scientific
7D
-9.0%
1Y
-46.2%
CNC
US$53.34
Centene
7D
27.5%
1Y
-11.3%

CNC: Policy And Exchange Uncertainty Will Pressure Margins And Constrain Upside

Analysts have trimmed the fair value estimate for Centene to $43.47 from $44.18, reflecting updated views on revenue growth, margin potential, and a lower expected future P/E multiple, even as several recent price target revisions highlight ongoing debate around the stock. Analyst Commentary Recent Street research paints a mixed picture for Centene, with several firms adjusting price targets and ratings as they reassess the company after Q4 results, updated guidance, and regulatory developments.
MDT
US$80.00
Medtronic
7D
-4.0%
1Y
-5.7%
ISRG
US$457.78
Intuitive Surgical
7D
-5.1%
1Y
-13.5%
CVS
US$82.09
CVS Health
7D
5.3%
1Y
21.7%

CVS: Medicare Advantage Turnaround And FTC Settlement Will Support Future Earnings

CVS Health's analyst price targets have edged higher by a few dollars, as analysts factor in slightly stronger revenue and margin assumptions, a modestly lower discount rate, and a somewhat lower future P/E multiple in light of recent research that highlights Medicare Advantage exposure, potential earnings stability in pharmacy, and reduced regulatory uncertainty tied to a possible FTC settlement. Analyst Commentary Recent research on CVS Health reflects a mix of cautious optimism and ongoing concern, with analysts adjusting price targets by only a few dollars in either direction as they reassess earnings quality, regulatory risks, and Medicare Advantage exposure.
SMMT
US$16.12
Summit Therapeutics
7D
-27.0%
1Y
-42.2%